Year-over-year, this metric declined by 98.9%, from $46.30M to $501.00K. Over 4 years (FY 2021 to FY 2025), Payment for contingent consideration liability (financing) shows an upward trend with a 91.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates higher cash outflows for past acquisitions, potentially signaling successful performance milestones being met by acquired entities.
Represents cash outflows related to the settlement of earn-out or milestone payments for acquired businesses that exceed...
Common in high-growth medical device companies that frequently acquire smaller technology firms.
cf_abbv_payment_contingent_consideration_financing| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $870.25K | $870.25K | $870.25K | $1.75M | $55.00K | $3.15M | $0.00 | $3.83M | $3.83M | $3.83M | $3.83M | $18.57M | $0.00 | $0.00 | $6.79M | $46.30M | $0.00 | $0.00 | $0.00 | $501.00K |
| QoQ Change | — | +0.0% | +0.0% | +101.3% | -96.9% | >999% | -100.0% | — | +0.0% | +0.0% | +0.0% | +384.8% | -100.0% | — | — | +581.5% | -100.0% | — | — | — |
| YoY Change | — | — | — | — | -93.7% | +262.2% | -100.0% | +118.6% | >999% | +21.5% | — | +384.8% | -100.0% | -100.0% | +77.4% | +149.3% | — | — | -100.0% | -98.9% |